Cross-fire doses from β-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics

Physics in Medicine and Biology

Volumn 53, Issue 7, 2008, Pages 1909-1920

  Enger, S A ^a   Hartman, T ^b   Carlsson, J ^a   Lundqvist, H ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS-FIRE RADIATION; METASTASES; PRIMARY TUMORS; THEORETICAL STUDY;

ABSORPTION; BIOCONVERSION; MATHEMATICAL MODELS; RADIOACTIVITY; RADIOTHERAPY; TUMORS;

RADIOISOTOPES;

GADOLINIUM; GADOLINIUM 159; IODINE 131; LUTETIUM 177; PHOSPHORUS 32; RADIOISOTOPE; RHENIUM 188; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; BETA RADIATION; BREAST CANCER; CALCULATION; CANCER RADIOTHERAPY; DRUG TARGETING; ELECTRON; ENERGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MONTE CARLO METHOD; PRIORITY JOURNAL; RADIATION DOSE; THEORETICAL STUDY;

BETA RAYS; BREAST NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MODELS, THEORETICAL; MONTE CARLO METHOD; NEOPLASM METASTASIS; RADIOISOTOPES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; SOFTWARE; TREATMENT OUTCOME;

EID: 42449144785     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/53/7/007     Document Type: Article

References (19)

1. Al-Kuraya K et al 2004 Prognostic relevance of gene amplifications and coamplifications in breast cancer Cancer Res. 64 8534-40
2. Bardiés M and Chatal J-F 1994 Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres Phys. Med. Biol. 39 961-81
3. Carlsson J, Aronsson E F, Hietala S O, Stigbrand T and Tennvall J 2003 Tumour therapy with radionuclides: assessment of progress and problems Radiother. Oncol. 66 107-17
4. Carlsson J et al 2004 Her2 expression in breast cancer primary tumors and corresponding metastases. Original data and literature review Br. J. Cancer 90 2344-8
5. Carrier J F, Archambault L, Beaulieu L and Roy R 2004 Validation of GEANT4, an object-oriented Monte Carlo toolkit for simulations in medical physics Med. Phys. 3 484-92
6. 3] octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size J. Nucl. Med. 42 1841-6
7. De Jong M, Breeman W A P, Valkema R, Bernard B F and Krenning E P 2005 Combination radionuclide therapy using 177Lu and 90Y-labeled Somatostatin analogs J. Nucl. Med. 46 13S-17S
8. DeNardo S J 2005 Tumor-targeted radionuclide therapy: trial design driven by patient dosimetry J. Nucl. Med. 41 104-6
9. Fisher D R 2003 Assessments for high dose radionuclide therapy treatment planning Radiat. Prot. Dosim. 105 581-6
10. Kassis A I and Adelstein S J 2005 Radiobiologic principles in radionuclide therapy J. Nucl. Med. 46 4S-12S
11. 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin J. Nucl. Med. 7 1224-32
12. Larson S M and Krenning E P 2005 A pragmatic perspective on molecular targeted radionuclide therapy J. Nucl. Med. 46 1S-3S
13. O'Donoghue J A, Bardies M and Wheldon T E 1995 Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides J. Nucl. Med. 36 1902-9
14. Pegram M D, Konecny G and Slamon D J 2000 The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer Cancer Treat. Res. 103 57-75
15. Sjostrom J et al 2002 C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer Eur. J. Cancer 38 535-42
16. Sparks R B, Crowe E A, Wong F C, Toohey R E and Siegel J A 2002 Radiation dose distributions in normal tissue adjacent to tumors containing 131I or 90Y: the potential for toxicity J. Nucl. Med. 43 1110-4
17. Weibel E R and Elias H 1967 Introduction to stereologic principles Quantitative Methods in Morphology ed Weibel E R and Elias H (Berlin: Springer) pp 89-98
18. WHO 2002 The World Health Report WHO http://www.who.int/whr/2002/en/
19. Witton C J, Reeves J R, Going J J, Cooke T G and Bartlett J M 2003 Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer J. Pathol. 200 279-81